89bio (ETNB) Earnings Date & Reports

A.I. Advisor

published Earnings

ETNB is expected to report earnings to rise 36.81% to -65 cents per share on November 07

Q3'24

Est.

$-0.66

Q2'24

Beat

by $0.08

Q1'24

Missed

by $0.08

Q4'23

Missed

by $0.01

Q3'23

Beat

by $0.08

The last earnings report on August 05 showed earnings per share of -47 cents, beating the estimate of -56 cents. With 653.33K shares outstanding, the current market capitalization sits at 768.38M.

View a ticker or compare two or three

Compare

ETNB

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if shorted

View Trends For ETNB
(Try 14 days for $1 only)

Ad is loading...

A.I.Advisor

published price charts

View to see Real Time Patterns for ETNB (Try 14 days for $1 only)

A.I. Advisor

published General Information

General Information

a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

142 Sansome Street

Phone

+1 415 432-9270

Employees

Web

https://www.89bio.com